Search

Displaying results 831 - 840 of 4575 in total
  1. Drug

    Fosfomycin

    go.drugbank.com/drugs/DB00828
    ApprovedInvestigational

    Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by _Streptomyces fradiae_.

  2. Drug

    Ichthammol

    go.drugbank.com/drugs/DB11341
    Approved

    It is an ammonium salt of dark sulfonated shale oil (bituminous schists) produced via distillation of the oil followed by sulfonation and neutralization.

  3. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression across metastases (i.e. to identify sites that no longer express ER) without … [A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna.

  4. Drug

    Piperazine

    go.drugbank.com/drugs/DB00592
    ApprovedVet approvedWithdrawn

    Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. … Piperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism.

  5. Drug

    Simoctocog alfa

    go.drugbank.com/drugs/DB09108
    Approved

    Full human post-translational modifications via elimination of potentially immunogenic glycosylation patterns found in non-human cell lines led to decreased immunogenicity and longer half-life [A31525] … The harvested product is concentrated and purified by a series of chromatography steps.

  6. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  8. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.

  9. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals … In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a similar indication as approved by the FDA.

  10. Drug

    Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16727
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen